PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19785755-4 2009 RESULTS: Using real time RT-PCR and Western blotting, chronic NMDA administration was shown to decrease mRNA and protein levels of anti-apoptotic markers Bcl-2 and BDNF, and of their transcription factor phospho-CREB in the cortex. N-Methylaspartate 62-66 brain-derived neurotrophic factor Rattus norvegicus 164-168 16983663-5 2006 We found that the amplitude of the N-methyl-D-aspartate (NMDA) component of the evoked excitatory postsynaptic currents (NMDA-EPSC) was increased by application of BDNF. N-Methylaspartate 35-55 brain-derived neurotrophic factor Rattus norvegicus 164-168 18339694-0 2008 Emergence of brain-derived neurotrophic factor-induced postsynaptic potentiation of NMDA currents during the postnatal maturation of the Kolliker-Fuse nucleus of rat. N-Methylaspartate 84-88 brain-derived neurotrophic factor Rattus norvegicus 13-46 18339694-9 2008 Subsequent experiments revealed that bath-application of BDNF progressively potentiated these repetitively evoked NMDA currents only in intermediate and juvenile age groups. N-Methylaspartate 114-118 brain-derived neurotrophic factor Rattus norvegicus 57-61 18339694-10 2008 Pharmacological inhibition of protein kinase C (PKC), as a downstream component of the BDNF-tyrosine kinase B receptor (trkB) signalling, prevented BDNF-induced potentiation of NMDA currents. N-Methylaspartate 177-181 brain-derived neurotrophic factor Rattus norvegicus 87-91 18339694-11 2008 BDNF-induced potentiation of NMDA currents in later developmental stages might be essential for synaptic plasticity during the adaptation of the breathing pattern in response to peripheral/central commands. N-Methylaspartate 29-33 brain-derived neurotrophic factor Rattus norvegicus 0-4 17376001-2 2007 Here, patch-clamp recording was used to study BDNF-induced modification of synaptic and NMDA-evoked responses in transverse spinal slices from lumbar (L2-L5) spinal cord of rats from P3 to P21 following complete spinal cord transection at P2. N-Methylaspartate 88-92 brain-derived neurotrophic factor Rattus norvegicus 46-50 17086548-0 2007 Role of brain-derived neurotrophic factor in the protective action of N-methyl-D-aspartate in the apoptotic death of cerebellar granule neurons induced by low potassium. N-Methylaspartate 70-90 brain-derived neurotrophic factor Rattus norvegicus 8-41 17376001-1 2007 We previously reported that the pronociceptive neurotrophin brain-derived neurotrophic factor (BDNF) induces facilitation of C-fiber evoked EPSCs and NMDA currents in lamina II neurons of rats up to P40. N-Methylaspartate 150-154 brain-derived neurotrophic factor Rattus norvegicus 95-99 16983663-5 2006 We found that the amplitude of the N-methyl-D-aspartate (NMDA) component of the evoked excitatory postsynaptic currents (NMDA-EPSC) was increased by application of BDNF. N-Methylaspartate 57-61 brain-derived neurotrophic factor Rattus norvegicus 164-168 16983663-5 2006 We found that the amplitude of the N-methyl-D-aspartate (NMDA) component of the evoked excitatory postsynaptic currents (NMDA-EPSC) was increased by application of BDNF. N-Methylaspartate 121-125 brain-derived neurotrophic factor Rattus norvegicus 164-168 16800825-2 2006 We have hypothesized that the chronic blockade of NMDA with phencyclidine (PCP) may have a different effect on BDNF synthesis at different stages of development. N-Methylaspartate 50-54 brain-derived neurotrophic factor Rattus norvegicus 111-115 16402025-11 2005 The exogenous administration of BDNF prevented the dephosphorylation of Akt in N-Shc/ShcC-positive RGCs and significantly suppressed the NMDA-induced RGC death. N-Methylaspartate 137-141 brain-derived neurotrophic factor Rattus norvegicus 32-36 16125841-5 2005 This increase of activity is suggested to be mediated by a potentiation of the postsynaptic NMDA receptors because it has been found that BDNF potentiates the NMDA-evoked depolarization in cultures incubated with BDNF for 10 min. N-Methylaspartate 92-96 brain-derived neurotrophic factor Rattus norvegicus 138-142 16125841-5 2005 This increase of activity is suggested to be mediated by a potentiation of the postsynaptic NMDA receptors because it has been found that BDNF potentiates the NMDA-evoked depolarization in cultures incubated with BDNF for 10 min. N-Methylaspartate 92-96 brain-derived neurotrophic factor Rattus norvegicus 213-217 15749335-0 2005 N-methyl-D-aspartic acid-induced and Ca-dependent neuronal swelling and its retardation by brain-derived neurotrophic factor in the epileptic hippocampus. N-Methylaspartate 0-24 brain-derived neurotrophic factor Rattus norvegicus 91-124 15744743-1 2005 N-Methyl-D-aspartate (NMDA) at a subtoxic concentration (100 microM) promotes neuronal survival against glutamate-mediated excitotoxicity via a brain-derived neurotrophic factor (BDNF) autocrine loop in cultured cerebellar granule cells. N-Methylaspartate 0-20 brain-derived neurotrophic factor Rattus norvegicus 144-177 15744743-1 2005 N-Methyl-D-aspartate (NMDA) at a subtoxic concentration (100 microM) promotes neuronal survival against glutamate-mediated excitotoxicity via a brain-derived neurotrophic factor (BDNF) autocrine loop in cultured cerebellar granule cells. N-Methylaspartate 0-20 brain-derived neurotrophic factor Rattus norvegicus 179-183 15744743-1 2005 N-Methyl-D-aspartate (NMDA) at a subtoxic concentration (100 microM) promotes neuronal survival against glutamate-mediated excitotoxicity via a brain-derived neurotrophic factor (BDNF) autocrine loop in cultured cerebellar granule cells. N-Methylaspartate 22-26 brain-derived neurotrophic factor Rattus norvegicus 144-177 15744743-1 2005 N-Methyl-D-aspartate (NMDA) at a subtoxic concentration (100 microM) promotes neuronal survival against glutamate-mediated excitotoxicity via a brain-derived neurotrophic factor (BDNF) autocrine loop in cultured cerebellar granule cells. N-Methylaspartate 22-26 brain-derived neurotrophic factor Rattus norvegicus 179-183 15764082-6 2004 RESULTS: AAV.CMV.bFGF and AAV.CBA.BDNF were neuroprotective against NMDA injection 1 month post-treatment. N-Methylaspartate 68-72 brain-derived neurotrophic factor Rattus norvegicus 34-38 14664909-2 2003 Glutamate N-methl-D-aspartate (NMDA) receptor activation increases BDNF expression, while BDNF facilitates NMDA activity, with both involved in spatial learning. N-Methylaspartate 31-35 brain-derived neurotrophic factor Rattus norvegicus 67-71 15306120-3 2004 A 100 microM NMDA alone decreased NT-3, increased BDNF, but had no effect on NGF or FGF2. N-Methylaspartate 13-17 brain-derived neurotrophic factor Rattus norvegicus 50-54 14664909-12 2003 These data suggest that BDNF expression is important for NMDA-dependent learning and memory. N-Methylaspartate 57-61 brain-derived neurotrophic factor Rattus norvegicus 24-28 12853306-6 2003 One of the major mechanisms of NMDA neuroprotection involves the activation of NMDA receptors leading to the rapid release of brain-derived neurotrophic factor (BDNF). N-Methylaspartate 31-35 brain-derived neurotrophic factor Rattus norvegicus 126-159 12853306-6 2003 One of the major mechanisms of NMDA neuroprotection involves the activation of NMDA receptors leading to the rapid release of brain-derived neurotrophic factor (BDNF). N-Methylaspartate 31-35 brain-derived neurotrophic factor Rattus norvegicus 161-165 12454046-7 2002 A significant increase in the protection against NMDA was observed in the neuroretinal cells cultured with BDNF-transfected IPE cells than in those cultured with nontransfected IPE cells (P = 0.0029) or with nontreated cells (P = 0.0010). N-Methylaspartate 49-53 brain-derived neurotrophic factor Rattus norvegicus 107-111 11404434-9 2001 The NMDA antagonist d-AP-5 inhibited electrically evoked BDNF release. N-Methylaspartate 4-8 brain-derived neurotrophic factor Rattus norvegicus 57-61 11860475-6 2001 Bath applied NMDA antagonists APV and MK-801 abolished both facilitatory and inhibitory actions of BDNF on the AMPA/kainate responses indicating the requirement for functional NMDA receptors. N-Methylaspartate 13-17 brain-derived neurotrophic factor Rattus norvegicus 99-103 11860475-9 2001 Furthermore, BDNF enhanced NMDA-induced depolarization of the motoneuron in the presence of tetrodotoxin (TTX), thus, confirming its facilitatory effect on motoneuron NMDA receptors. N-Methylaspartate 27-31 brain-derived neurotrophic factor Rattus norvegicus 13-17 11860475-10 2001 Bath application of either BDNF or NMDA depressed the monosynaptic EPSP after selective blockade of postsynaptic NMDA receptors indicating a role for presynaptic NMDA receptors in BDNF-induced inhibitory action. N-Methylaspartate 35-39 brain-derived neurotrophic factor Rattus norvegicus 180-184 12395101-2 2002 Recent evidence suggests that BDNF modulates NMDA responses, by a yet unknown mechanism. N-Methylaspartate 45-49 brain-derived neurotrophic factor Rattus norvegicus 30-34 11461961-2 2001 A candidate sequence from the 5" flanking region of exon 3 of the rat brain-derived neurotrophic factor (BDNF) gene was used to show that exposure of rat cerebellar granule cells to 100 microM NMDA activated a specific DNA binding activity that was blocked by the NMDA receptor antagonist MK-801. N-Methylaspartate 193-197 brain-derived neurotrophic factor Rattus norvegicus 70-103 11461961-2 2001 A candidate sequence from the 5" flanking region of exon 3 of the rat brain-derived neurotrophic factor (BDNF) gene was used to show that exposure of rat cerebellar granule cells to 100 microM NMDA activated a specific DNA binding activity that was blocked by the NMDA receptor antagonist MK-801. N-Methylaspartate 193-197 brain-derived neurotrophic factor Rattus norvegicus 105-109 11461961-5 2001 Furthermore, nuclear extracts prepared from neurons treated with NMDA and the double-stranded NF-kappaB oligonucleotide showed reduced DNA binding activity to the target sequence, supporting the idea that NF-kappaB may be involved in the transcriptional activation of the BDNF gene. N-Methylaspartate 65-69 brain-derived neurotrophic factor Rattus norvegicus 272-276 11461961-7 2001 Relative to GAPDH mRNA levels and compared with untreated neurons, NMDA increased exon 3-specific BDNF mRNA twofold. N-Methylaspartate 67-71 brain-derived neurotrophic factor Rattus norvegicus 98-102 11461961-8 2001 In contrast, pretreatment of neurons with the NF-kappaB target DNA abolished the increase in BDNF mRNA following addition of NMDA. N-Methylaspartate 125-129 brain-derived neurotrophic factor Rattus norvegicus 93-97 11082487-6 2000 RESULTS: Morphometric analysis of retinal damage in NMDA-injected eyes showed that BDNF could protect inner retinal cells from glutamate receptor-mediated neuronal death. N-Methylaspartate 52-56 brain-derived neurotrophic factor Rattus norvegicus 83-87 11303760-3 2001 BDNF protein expression was reduced by NMDA and much more markedly by serum deprivation (approximately 28 and 93% reduction respectively). N-Methylaspartate 39-43 brain-derived neurotrophic factor Rattus norvegicus 0-4 11082487-0 2000 Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death. N-Methylaspartate 74-78 brain-derived neurotrophic factor Rattus norvegicus 27-60 11082487-1 2000 PURPOSE: To determine if brain-derived neurotrophic factor (BDNF) has a neuroprotective effect against N-methyl-D-aspartate (NMDA)-induced cell death in retina. N-Methylaspartate 103-123 brain-derived neurotrophic factor Rattus norvegicus 25-58 11082487-1 2000 PURPOSE: To determine if brain-derived neurotrophic factor (BDNF) has a neuroprotective effect against N-methyl-D-aspartate (NMDA)-induced cell death in retina. N-Methylaspartate 103-123 brain-derived neurotrophic factor Rattus norvegicus 60-64 11082487-1 2000 PURPOSE: To determine if brain-derived neurotrophic factor (BDNF) has a neuroprotective effect against N-methyl-D-aspartate (NMDA)-induced cell death in retina. N-Methylaspartate 125-129 brain-derived neurotrophic factor Rattus norvegicus 25-58 11082487-1 2000 PURPOSE: To determine if brain-derived neurotrophic factor (BDNF) has a neuroprotective effect against N-methyl-D-aspartate (NMDA)-induced cell death in retina. N-Methylaspartate 125-129 brain-derived neurotrophic factor Rattus norvegicus 60-64 11082487-9 2000 CONCLUSIONS: Exogenous BDNF can protect inner retinal cells (possible RGCs and amacrine cells) from NMDA-induced neuronal death. N-Methylaspartate 100-104 brain-derived neurotrophic factor Rattus norvegicus 23-27 10748141-4 2000 Although the promoter activations at 25 and 50 mm KCl were different, BDNF-PIII was activated by either the Ca(2+) influx through NMDA-R or L-VDCC, whereas BDNF-PI was predominantly by the Ca(2+) influx through L-VDCC. N-Methylaspartate 130-134 brain-derived neurotrophic factor Rattus norvegicus 70-74 10321491-0 1999 NMDA induces BDNF expression in the albino rat retina in vivo. N-Methylaspartate 0-4 brain-derived neurotrophic factor Rattus norvegicus 13-17 10591601-11 1999 Treatment with Brain Derived Neurotrophic Factor (BDNF) prevented ethanol sensitization to NMDA excitotoxicity. N-Methylaspartate 91-95 brain-derived neurotrophic factor Rattus norvegicus 15-48 10591601-11 1999 Treatment with Brain Derived Neurotrophic Factor (BDNF) prevented ethanol sensitization to NMDA excitotoxicity. N-Methylaspartate 91-95 brain-derived neurotrophic factor Rattus norvegicus 50-54 10366647-0 1999 Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. N-Methylaspartate 75-79 brain-derived neurotrophic factor Rattus norvegicus 0-33 10321491-1 1999 The effect of an intravitreal injection of NMDA on the expression of brain-derived neurotrophic factor (BDNF) in retinal ganglion cells was investigated in rats. N-Methylaspartate 43-47 brain-derived neurotrophic factor Rattus norvegicus 69-102 10321491-1 1999 The effect of an intravitreal injection of NMDA on the expression of brain-derived neurotrophic factor (BDNF) in retinal ganglion cells was investigated in rats. N-Methylaspartate 43-47 brain-derived neurotrophic factor Rattus norvegicus 104-108 10321491-2 1999 Forty-eight hours after intravitreal injection of NMDA retinal ganglion cell BDNF immunoreactivity was practically obliterated, as was the choline acetyltransferase (ChAT) immunoreactivity associated with a subset of amacrine cells. N-Methylaspartate 50-54 brain-derived neurotrophic factor Rattus norvegicus 77-81 10321491-3 1999 However, 2h following treatment with NMDA the BDNF immunoreactivity and BDNF mRNA associated with the ganglion cells was enhanced while the amacrine cell ChAT immunoreactivity was clearly reduced and the levels of mRNA coding for rhodopsin and Thy-1 did not change. N-Methylaspartate 37-41 brain-derived neurotrophic factor Rattus norvegicus 46-50 10321491-3 1999 However, 2h following treatment with NMDA the BDNF immunoreactivity and BDNF mRNA associated with the ganglion cells was enhanced while the amacrine cell ChAT immunoreactivity was clearly reduced and the levels of mRNA coding for rhodopsin and Thy-1 did not change. N-Methylaspartate 37-41 brain-derived neurotrophic factor Rattus norvegicus 72-76 10321491-4 1999 However, 4h after NMDA injection the increase in BDNF mRNA was now no longer apparent. N-Methylaspartate 18-22 brain-derived neurotrophic factor Rattus norvegicus 49-53 10321491-5 1999 The results show that synthesis of BDNF is increased in the ganglion cells immediately following an insult by NMDA. N-Methylaspartate 110-114 brain-derived neurotrophic factor Rattus norvegicus 35-39 9739998-3 1998 Exposure of cultured cortical neurons to BDNF (100 ng/ml) for 24 h produced a significant decrease in the NMDA-induced whole-cell currents sensitive to the NR2B subunit selective NMDA receptor antagonist, CP-101,606, suggesting a relative decrease in NR2B subunit expression. N-Methylaspartate 106-110 brain-derived neurotrophic factor Rattus norvegicus 41-45 9742162-3 1998 In these cells, brain-derived neurotrophic factor (BDNF) and basic fibroblast growth factor (FGF2) prevent the excitotoxic effect of NMDA. N-Methylaspartate 133-137 brain-derived neurotrophic factor Rattus norvegicus 16-49 9742162-3 1998 In these cells, brain-derived neurotrophic factor (BDNF) and basic fibroblast growth factor (FGF2) prevent the excitotoxic effect of NMDA. N-Methylaspartate 133-137 brain-derived neurotrophic factor Rattus norvegicus 51-55 9742162-9 1998 BDNF and FGF2 reduced the NMDA-mediated [Ca2+]i increase with a time dependency that correlates with their ability to decrease NR2A and NR2C subunit expression, suggesting that these trophic factors also induce a functional downregulation of the NMDA receptor. N-Methylaspartate 26-30 brain-derived neurotrophic factor Rattus norvegicus 0-4 9886060-0 1999 Evidence that brain-derived neurotrophic factor neuroprotection is linked to its ability to reverse the NMDA-induced inactivation of protein kinase C in cortical neurons. N-Methylaspartate 104-108 brain-derived neurotrophic factor Rattus norvegicus 14-47 9886060-2 1999 Exposing embryonic day 18 primary rat cortical neurons to 50 microM NMDA or 50 microM glutamate for 10 min caused approximately 80% cell death over the next 24 h, but excitotoxic death was largely averted, i.e., by 70-80%, in cells pretreated with brain-derived neurotrophic factor (BDNF). N-Methylaspartate 68-72 brain-derived neurotrophic factor Rattus norvegicus 248-281 9886060-2 1999 Exposing embryonic day 18 primary rat cortical neurons to 50 microM NMDA or 50 microM glutamate for 10 min caused approximately 80% cell death over the next 24 h, but excitotoxic death was largely averted, i.e., by 70-80%, in cells pretreated with brain-derived neurotrophic factor (BDNF). N-Methylaspartate 68-72 brain-derived neurotrophic factor Rattus norvegicus 283-287 9886060-3 1999 An 8-h preexposure to BDNF (50-100 ng/ml) maximally protected cortical cells from the effects of NMDA and glutamate, although the transient application of BDNF between 8 and 4 h before NMDA was equally protective. N-Methylaspartate 97-101 brain-derived neurotrophic factor Rattus norvegicus 22-26 9886060-3 1999 An 8-h preexposure to BDNF (50-100 ng/ml) maximally protected cortical cells from the effects of NMDA and glutamate, although the transient application of BDNF between 8 and 4 h before NMDA was equally protective. N-Methylaspartate 185-189 brain-derived neurotrophic factor Rattus norvegicus 22-26 9886060-4 1999 These effects of BDNF were abolished at supralethal, i.e., >100 microM, NMDA concentrations. N-Methylaspartate 75-79 brain-derived neurotrophic factor Rattus norvegicus 17-21 9886060-5 1999 It is significant that BDNF pretreatment prevented the inactivation of PKC in cortical cells normally seen 30 min to 2 h following lethal NMDA or glutamate exposure. N-Methylaspartate 138-142 brain-derived neurotrophic factor Rattus norvegicus 23-27 8813618-7 1996 Of note, short-term pre-treatment with brain-derived neurotrophic factor (BDNF; 5-50 ng/ml) significantly potentiated NMDA-induced neurodegeneration. N-Methylaspartate 118-122 brain-derived neurotrophic factor Rattus norvegicus 39-72 9761465-12 1998 These results suggest that the gene expression of BDNF was enhanced by transient ischemia both in the hippocampus and the cerebral cortex and that the cerebral ischemia stimulated at least two different promoter- and neuron type-specific pathways regulating expression of the BDNF gene mediated by glutamate receptors of non-NMDA type and NMDA type. N-Methylaspartate 325-329 brain-derived neurotrophic factor Rattus norvegicus 50-54 9761465-12 1998 These results suggest that the gene expression of BDNF was enhanced by transient ischemia both in the hippocampus and the cerebral cortex and that the cerebral ischemia stimulated at least two different promoter- and neuron type-specific pathways regulating expression of the BDNF gene mediated by glutamate receptors of non-NMDA type and NMDA type. N-Methylaspartate 325-329 brain-derived neurotrophic factor Rattus norvegicus 276-280 9761465-12 1998 These results suggest that the gene expression of BDNF was enhanced by transient ischemia both in the hippocampus and the cerebral cortex and that the cerebral ischemia stimulated at least two different promoter- and neuron type-specific pathways regulating expression of the BDNF gene mediated by glutamate receptors of non-NMDA type and NMDA type. N-Methylaspartate 339-343 brain-derived neurotrophic factor Rattus norvegicus 50-54 9761465-12 1998 These results suggest that the gene expression of BDNF was enhanced by transient ischemia both in the hippocampus and the cerebral cortex and that the cerebral ischemia stimulated at least two different promoter- and neuron type-specific pathways regulating expression of the BDNF gene mediated by glutamate receptors of non-NMDA type and NMDA type. N-Methylaspartate 339-343 brain-derived neurotrophic factor Rattus norvegicus 276-280 9666119-0 1998 Brain-derived neurotrophic factor rapidly potentiates synaptic transmission through NMDA, but suppresses it through non-NMDA receptors in rat hippocampal neuron. N-Methylaspartate 84-88 brain-derived neurotrophic factor Rattus norvegicus 0-33 9666119-3 1998 In the presence of AP5, a N-methyl-D-aspartate (NMDA) antagonist, BDNF depressed the EPSCs. N-Methylaspartate 26-46 brain-derived neurotrophic factor Rattus norvegicus 66-70 9666119-3 1998 In the presence of AP5, a N-methyl-D-aspartate (NMDA) antagonist, BDNF depressed the EPSCs. N-Methylaspartate 48-52 brain-derived neurotrophic factor Rattus norvegicus 66-70 9666119-4 1998 In contrast, BDNF enhanced the EPSCs in the presence of a non-NMDA antagonist CNQX. N-Methylaspartate 62-66 brain-derived neurotrophic factor Rattus norvegicus 13-17 9666119-5 1998 Our results suggest that BDNF acutely activates synaptic transmission via NMDA, but suppresses it via non-NMDA receptors in the hippocampus. N-Methylaspartate 74-78 brain-derived neurotrophic factor Rattus norvegicus 25-29 9356388-5 1997 The effects of BDNF on NMDA-activated currents were examined in greater detail. N-Methylaspartate 23-27 brain-derived neurotrophic factor Rattus norvegicus 15-19 9356388-9 1997 The enhancement of NMDA-activated currents by BDNF was observed using both perforated and whole cell patch recording techniques and could be demonstrated in outside-out patches. N-Methylaspartate 19-23 brain-derived neurotrophic factor Rattus norvegicus 46-50 9356388-14 1997 Modulation of NMDA responses by BDNF was dependent on the concentration of extracellular glycine. N-Methylaspartate 14-18 brain-derived neurotrophic factor Rattus norvegicus 32-36 9356388-16 1997 However, the competitive glycine-site antagonist 7-chloro-kynurenic acid blocked the enhancement by BDNF without shifting the dose-inhibition relationship for this antagonist, and Mg2+ consistently depressed the potentiation of NMDA-evoked currents by BDNF, indicating that BDNF does not alter glycine affinity. N-Methylaspartate 228-232 brain-derived neurotrophic factor Rattus norvegicus 252-256 9356388-16 1997 However, the competitive glycine-site antagonist 7-chloro-kynurenic acid blocked the enhancement by BDNF without shifting the dose-inhibition relationship for this antagonist, and Mg2+ consistently depressed the potentiation of NMDA-evoked currents by BDNF, indicating that BDNF does not alter glycine affinity. N-Methylaspartate 228-232 brain-derived neurotrophic factor Rattus norvegicus 252-256 9674574-0 1998 BDNF gene transcripts in mesencephalic neurons and its differential regulation by NMDA. N-Methylaspartate 82-86 brain-derived neurotrophic factor Rattus norvegicus 0-4 9674574-5 1998 Quantitative RT-PCR analysis of mesencephalic neurons revealed that NMDA, but not kainate treatment, significantly increased BDNF mRNAs derived from exons 1b and 1d. N-Methylaspartate 68-72 brain-derived neurotrophic factor Rattus norvegicus 125-129 8813618-7 1996 Of note, short-term pre-treatment with brain-derived neurotrophic factor (BDNF; 5-50 ng/ml) significantly potentiated NMDA-induced neurodegeneration. N-Methylaspartate 118-122 brain-derived neurotrophic factor Rattus norvegicus 74-78 8635431-7 1996 The noncompetitive N-methyl-D-aspartate (NMDA) antagonist ketamine blocked NGF, BDNF, and trkB mRNA increases in the hippocampus and cerebral cortex, but not in the amygdala and piriform cortex. N-Methylaspartate 19-39 brain-derived neurotrophic factor Rattus norvegicus 80-84 8635431-7 1996 The noncompetitive N-methyl-D-aspartate (NMDA) antagonist ketamine blocked NGF, BDNF, and trkB mRNA increases in the hippocampus and cerebral cortex, but not in the amygdala and piriform cortex. N-Methylaspartate 41-45 brain-derived neurotrophic factor Rattus norvegicus 80-84 31032138-12 2019 These results suggest that either NMDA or AMPA/kainate receptor antagonists, acting at least partially through hippocampal BDNF, may be of therapeutic potential in alcohol use disorder. N-Methylaspartate 34-38 brain-derived neurotrophic factor Rattus norvegicus 123-127 7854071-7 1994 Pretreatment with the non-competitive NMDA antagonist MK-801 (2 mg/kg, 30 min before the insult), partially blocked the increase in both BDNF and NGF mRNAs, as well as the decrease in NT3, in the contralateral hippocampus. N-Methylaspartate 38-42 brain-derived neurotrophic factor Rattus norvegicus 137-141 8106000-0 1993 NMDA-stimulated expression of BDNF mRNA in cultured cerebellar granule neurones. N-Methylaspartate 0-4 brain-derived neurotrophic factor Rattus norvegicus 30-34 8106000-3 1993 This BDNF and mRNA upregulation was inhibited by dizocilpine (MK-801), the noncompetitive blocker of N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors, and mimicked by NMDA. N-Methylaspartate 123-127 brain-derived neurotrophic factor Rattus norvegicus 5-9 8106000-4 1993 Continuous (up to 5 h) culture exposure to non-toxic NMDA concentration resulted in a prolonged increase in BDNF mRNA expression and enhanced neuronal resistance to glutamate toxicity. N-Methylaspartate 53-57 brain-derived neurotrophic factor Rattus norvegicus 108-112 8106000-6 1993 The mechanisms responsible for NMDA-triggered BDNF upregulation and neuroprotection might be important in the compensatory response of brain to excitotoxicity. N-Methylaspartate 31-35 brain-derived neurotrophic factor Rattus norvegicus 46-50 8247360-2 1993 This BDNF expression was blocked by the N-methyl-D-aspartate (NMDA) antagonist dizocilpine maleate (MK-801), which also blocked LTP induction, and by sodium pentobarbital, which shortens LTP persistence. N-Methylaspartate 40-60 brain-derived neurotrophic factor Rattus norvegicus 5-9 8247360-2 1993 This BDNF expression was blocked by the N-methyl-D-aspartate (NMDA) antagonist dizocilpine maleate (MK-801), which also blocked LTP induction, and by sodium pentobarbital, which shortens LTP persistence. N-Methylaspartate 62-66 brain-derived neurotrophic factor Rattus norvegicus 5-9 35090980-10 2022 Furthermore, MSG induced neurotoxicity was ameliorated through the activation of CREB and BDNF genes The mRNA expressions of CREB and BDNF were 1.5-fold higher and NMDA levels were 2.0-fold higher in treated groups compared to disease control group. N-Methylaspartate 164-168 brain-derived neurotrophic factor Rattus norvegicus 90-94 34054433-10 2021 Co-addition of NMDA significantly inhibited MK-801-induced upregulation of BDNF. N-Methylaspartate 15-19 brain-derived neurotrophic factor Rattus norvegicus 75-79 29042318-3 2018 In vivo, substance P release induced by intrathecal NMDA after priming with BDNF was inhibited by DAMGO. N-Methylaspartate 52-56 brain-derived neurotrophic factor Rattus norvegicus 76-80 20064115-0 2011 VIP, PACAP-38, BDNF and ADNP in NMDA-induced excitotoxicity in the rat retina. N-Methylaspartate 32-36 brain-derived neurotrophic factor Rattus norvegicus 15-19 27568334-18 2017 This protective effect of MgAT against NMDA-induced retinal cell apoptosis could be attributed to the reduction of retinal oxidative stress and activation of BDNF-related neuroprotective mechanisms. N-Methylaspartate 39-43 brain-derived neurotrophic factor Rattus norvegicus 158-162 25447233-7 2015 Taken together, these results suggest that the BDNF/SHP2/GluN2B-NMDA signaling cascade plays a vital role in the development of central sensitization and neuropathic pain after peripheral nerve injury. N-Methylaspartate 64-68 brain-derived neurotrophic factor Rattus norvegicus 47-51 24798187-11 2014 BDNF protein was reduced by NMDA in N-3 PUFA deficient rats, but protein levels of IL-1beta, NGF, and GFAP did not differ between groups. N-Methylaspartate 28-32 brain-derived neurotrophic factor Rattus norvegicus 0-4 20064115-1 2011 PURPOSE: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. N-Methylaspartate 83-87 brain-derived neurotrophic factor Rattus norvegicus 92-125 20064115-1 2011 PURPOSE: To evaluate the effect of intravitreal injection of N-methyl-D-aspartate (NMDA) on brain-derived neurotrophic factor (BDNF), pituitary adenylate cyclase-activating peptide-38 (PACAP-38), vasoactive intestinal peptide (VIP) and the VIP-associated glial protein activity-dependent neuroprotective protein (ADNP) in the rat retina. N-Methylaspartate 83-87 brain-derived neurotrophic factor Rattus norvegicus 127-131